A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)
We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy. The learning cohort was composed of 274 patients and the validation cohort of 323...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2020-10, Vol.20 (10), p.637-646 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 646 |
|---|---|
| container_issue | 10 |
| container_start_page | 637 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 20 |
| creator | Beltrán, Brady E. Villela, Luis Torres, Maria A. Otero, Victoria Fiad, Lorena Peña, Camila Cabrera, Maria E. León, Pilar Idrobo, Henry Castro, Denisse A. Paredes, Sally Perdomo, Ivan Abello, Virginia Rojas, Christine Ramirez-Ibargüen, Ana Candelaria, Myrna Pérez-Jacobo, Fernando Montaño-Figueroa, Efren Best, Carlos Goméz-De Leon, Andres Gómez-Almaguer, David Ruiz-Argüelles, Guillermo Hernández-Hernández, Jose Malpica, Luis Sotomayor, Eduardo M. Castillo, Jorge J. |
| description | We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy.
The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis.
In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P = .006) and the validation cohort (odds ratio, 0.49; P = .01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P = .04) and the validation cohort (hazard ratio, 1.80; P = .003).
The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR ≥ 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.
We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis. In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response and worse survival in the learning and the validation cohort. The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. |
| doi_str_mv | 10.1016/j.clml.2020.04.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2411110487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2152265020302111</els_id><sourcerecordid>2411110487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-f3069028d74b6e673392b797dac16e1e2c662f64848e8b9bc81bf6a221cfda473</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwAiyQl2WRYDuJkyA2w9AOlQJUUGBpOc5NxyMnDv6pNO_Kw-AobZd4Y_v6O8e-PknymuCMYMLeHTKpR51RTHGGiyyWniSnlJQ0pYw1Tx_XJT5JXjh3wLjCmDTPk5OcliQvm_o0-btBX4L2Kr2anFc-eGUmodEvoVUvlg0yA_J7QNfW3E4mMnI5DPBQ_wrBWzPvlU69SdvjOO-NPHpA3xc5UhO6jguYvEO_ld-jT2oYggPUCnsL6GO6Ba3RKhvFe7RBP3zoj-jSmhHd7BfOR4_NCFZJMaGdNWFe7l4lszVaDWAjdAfR2xnbg3XofHfRtm9fJs8GoR28up_Pkp-XFzfbz2n7bXe13bSpzEvm0yHHrMG07quiY8CqPG9oVzVVLyRhQIBKxujAirqooe6aTtakG5iglMihF0WVnyXnq298zp8AzvNRORkbExOY4DgtSBy4qBeUrqi0xjkLA5-tGoU9coL5kio_8CVVvqTKccFjKYre3PuHboT-UfIQYwQ-rADELu8UWO5k_HMJvbIgPe-N-p__P19Dtl4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2411110487</pqid></control><display><type>article</type><title>A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)</title><source>Elsevier ScienceDirect Journals</source><creator>Beltrán, Brady E. ; Villela, Luis ; Torres, Maria A. ; Otero, Victoria ; Fiad, Lorena ; Peña, Camila ; Cabrera, Maria E. ; León, Pilar ; Idrobo, Henry ; Castro, Denisse A. ; Paredes, Sally ; Perdomo, Ivan ; Abello, Virginia ; Rojas, Christine ; Ramirez-Ibargüen, Ana ; Candelaria, Myrna ; Pérez-Jacobo, Fernando ; Montaño-Figueroa, Efren ; Best, Carlos ; Goméz-De Leon, Andres ; Gómez-Almaguer, David ; Ruiz-Argüelles, Guillermo ; Hernández-Hernández, Jose ; Malpica, Luis ; Sotomayor, Eduardo M. ; Castillo, Jorge J.</creator><creatorcontrib>Beltrán, Brady E. ; Villela, Luis ; Torres, Maria A. ; Otero, Victoria ; Fiad, Lorena ; Peña, Camila ; Cabrera, Maria E. ; León, Pilar ; Idrobo, Henry ; Castro, Denisse A. ; Paredes, Sally ; Perdomo, Ivan ; Abello, Virginia ; Rojas, Christine ; Ramirez-Ibargüen, Ana ; Candelaria, Myrna ; Pérez-Jacobo, Fernando ; Montaño-Figueroa, Efren ; Best, Carlos ; Goméz-De Leon, Andres ; Gómez-Almaguer, David ; Ruiz-Argüelles, Guillermo ; Hernández-Hernández, Jose ; Malpica, Luis ; Sotomayor, Eduardo M. ; Castillo, Jorge J. ; The Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL]) ; Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</creatorcontrib><description>We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy.
The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis.
In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P = .006) and the validation cohort (odds ratio, 0.49; P = .01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P = .04) and the validation cohort (hazard ratio, 1.80; P = .003).
The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR ≥ 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.
We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis. In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response and worse survival in the learning and the validation cohort. The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2020.04.016</identifier><identifier>PMID: 32513598</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarkers ; DLBCL ; NLR ; Overall survival ; Prognostic factor</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2020-10, Vol.20 (10), p.637-646</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-f3069028d74b6e673392b797dac16e1e2c662f64848e8b9bc81bf6a221cfda473</citedby><cites>FETCH-LOGICAL-c356t-f3069028d74b6e673392b797dac16e1e2c662f64848e8b9bc81bf6a221cfda473</cites><orcidid>0000-0001-5330-9309 ; 0000-0002-7082-1846 ; 0000-0002-5478-714X ; 0000-0001-6188-8494</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2152265020302111$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32513598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beltrán, Brady E.</creatorcontrib><creatorcontrib>Villela, Luis</creatorcontrib><creatorcontrib>Torres, Maria A.</creatorcontrib><creatorcontrib>Otero, Victoria</creatorcontrib><creatorcontrib>Fiad, Lorena</creatorcontrib><creatorcontrib>Peña, Camila</creatorcontrib><creatorcontrib>Cabrera, Maria E.</creatorcontrib><creatorcontrib>León, Pilar</creatorcontrib><creatorcontrib>Idrobo, Henry</creatorcontrib><creatorcontrib>Castro, Denisse A.</creatorcontrib><creatorcontrib>Paredes, Sally</creatorcontrib><creatorcontrib>Perdomo, Ivan</creatorcontrib><creatorcontrib>Abello, Virginia</creatorcontrib><creatorcontrib>Rojas, Christine</creatorcontrib><creatorcontrib>Ramirez-Ibargüen, Ana</creatorcontrib><creatorcontrib>Candelaria, Myrna</creatorcontrib><creatorcontrib>Pérez-Jacobo, Fernando</creatorcontrib><creatorcontrib>Montaño-Figueroa, Efren</creatorcontrib><creatorcontrib>Best, Carlos</creatorcontrib><creatorcontrib>Goméz-De Leon, Andres</creatorcontrib><creatorcontrib>Gómez-Almaguer, David</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo</creatorcontrib><creatorcontrib>Hernández-Hernández, Jose</creatorcontrib><creatorcontrib>Malpica, Luis</creatorcontrib><creatorcontrib>Sotomayor, Eduardo M.</creatorcontrib><creatorcontrib>Castillo, Jorge J.</creatorcontrib><creatorcontrib>The Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</creatorcontrib><creatorcontrib>Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</creatorcontrib><title>A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy.
The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis.
In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P = .006) and the validation cohort (odds ratio, 0.49; P = .01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P = .04) and the validation cohort (hazard ratio, 1.80; P = .003).
The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR ≥ 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.
We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis. In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response and worse survival in the learning and the validation cohort. The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score.</description><subject>Biomarkers</subject><subject>DLBCL</subject><subject>NLR</subject><subject>Overall survival</subject><subject>Prognostic factor</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhSMEoqXwAiyQl2WRYDuJkyA2w9AOlQJUUGBpOc5NxyMnDv6pNO_Kw-AobZd4Y_v6O8e-PknymuCMYMLeHTKpR51RTHGGiyyWniSnlJQ0pYw1Tx_XJT5JXjh3wLjCmDTPk5OcliQvm_o0-btBX4L2Kr2anFc-eGUmodEvoVUvlg0yA_J7QNfW3E4mMnI5DPBQ_wrBWzPvlU69SdvjOO-NPHpA3xc5UhO6jguYvEO_ld-jT2oYggPUCnsL6GO6Ba3RKhvFe7RBP3zoj-jSmhHd7BfOR4_NCFZJMaGdNWFe7l4lszVaDWAjdAfR2xnbg3XofHfRtm9fJs8GoR28up_Pkp-XFzfbz2n7bXe13bSpzEvm0yHHrMG07quiY8CqPG9oVzVVLyRhQIBKxujAirqooe6aTtakG5iglMihF0WVnyXnq298zp8AzvNRORkbExOY4DgtSBy4qBeUrqi0xjkLA5-tGoU9coL5kio_8CVVvqTKccFjKYre3PuHboT-UfIQYwQ-rADELu8UWO5k_HMJvbIgPe-N-p__P19Dtl4</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Beltrán, Brady E.</creator><creator>Villela, Luis</creator><creator>Torres, Maria A.</creator><creator>Otero, Victoria</creator><creator>Fiad, Lorena</creator><creator>Peña, Camila</creator><creator>Cabrera, Maria E.</creator><creator>León, Pilar</creator><creator>Idrobo, Henry</creator><creator>Castro, Denisse A.</creator><creator>Paredes, Sally</creator><creator>Perdomo, Ivan</creator><creator>Abello, Virginia</creator><creator>Rojas, Christine</creator><creator>Ramirez-Ibargüen, Ana</creator><creator>Candelaria, Myrna</creator><creator>Pérez-Jacobo, Fernando</creator><creator>Montaño-Figueroa, Efren</creator><creator>Best, Carlos</creator><creator>Goméz-De Leon, Andres</creator><creator>Gómez-Almaguer, David</creator><creator>Ruiz-Argüelles, Guillermo</creator><creator>Hernández-Hernández, Jose</creator><creator>Malpica, Luis</creator><creator>Sotomayor, Eduardo M.</creator><creator>Castillo, Jorge J.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5330-9309</orcidid><orcidid>https://orcid.org/0000-0002-7082-1846</orcidid><orcidid>https://orcid.org/0000-0002-5478-714X</orcidid><orcidid>https://orcid.org/0000-0001-6188-8494</orcidid></search><sort><creationdate>202010</creationdate><title>A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)</title><author>Beltrán, Brady E. ; Villela, Luis ; Torres, Maria A. ; Otero, Victoria ; Fiad, Lorena ; Peña, Camila ; Cabrera, Maria E. ; León, Pilar ; Idrobo, Henry ; Castro, Denisse A. ; Paredes, Sally ; Perdomo, Ivan ; Abello, Virginia ; Rojas, Christine ; Ramirez-Ibargüen, Ana ; Candelaria, Myrna ; Pérez-Jacobo, Fernando ; Montaño-Figueroa, Efren ; Best, Carlos ; Goméz-De Leon, Andres ; Gómez-Almaguer, David ; Ruiz-Argüelles, Guillermo ; Hernández-Hernández, Jose ; Malpica, Luis ; Sotomayor, Eduardo M. ; Castillo, Jorge J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-f3069028d74b6e673392b797dac16e1e2c662f64848e8b9bc81bf6a221cfda473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers</topic><topic>DLBCL</topic><topic>NLR</topic><topic>Overall survival</topic><topic>Prognostic factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beltrán, Brady E.</creatorcontrib><creatorcontrib>Villela, Luis</creatorcontrib><creatorcontrib>Torres, Maria A.</creatorcontrib><creatorcontrib>Otero, Victoria</creatorcontrib><creatorcontrib>Fiad, Lorena</creatorcontrib><creatorcontrib>Peña, Camila</creatorcontrib><creatorcontrib>Cabrera, Maria E.</creatorcontrib><creatorcontrib>León, Pilar</creatorcontrib><creatorcontrib>Idrobo, Henry</creatorcontrib><creatorcontrib>Castro, Denisse A.</creatorcontrib><creatorcontrib>Paredes, Sally</creatorcontrib><creatorcontrib>Perdomo, Ivan</creatorcontrib><creatorcontrib>Abello, Virginia</creatorcontrib><creatorcontrib>Rojas, Christine</creatorcontrib><creatorcontrib>Ramirez-Ibargüen, Ana</creatorcontrib><creatorcontrib>Candelaria, Myrna</creatorcontrib><creatorcontrib>Pérez-Jacobo, Fernando</creatorcontrib><creatorcontrib>Montaño-Figueroa, Efren</creatorcontrib><creatorcontrib>Best, Carlos</creatorcontrib><creatorcontrib>Goméz-De Leon, Andres</creatorcontrib><creatorcontrib>Gómez-Almaguer, David</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo</creatorcontrib><creatorcontrib>Hernández-Hernández, Jose</creatorcontrib><creatorcontrib>Malpica, Luis</creatorcontrib><creatorcontrib>Sotomayor, Eduardo M.</creatorcontrib><creatorcontrib>Castillo, Jorge J.</creatorcontrib><creatorcontrib>The Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</creatorcontrib><creatorcontrib>Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beltrán, Brady E.</au><au>Villela, Luis</au><au>Torres, Maria A.</au><au>Otero, Victoria</au><au>Fiad, Lorena</au><au>Peña, Camila</au><au>Cabrera, Maria E.</au><au>León, Pilar</au><au>Idrobo, Henry</au><au>Castro, Denisse A.</au><au>Paredes, Sally</au><au>Perdomo, Ivan</au><au>Abello, Virginia</au><au>Rojas, Christine</au><au>Ramirez-Ibargüen, Ana</au><au>Candelaria, Myrna</au><au>Pérez-Jacobo, Fernando</au><au>Montaño-Figueroa, Efren</au><au>Best, Carlos</au><au>Goméz-De Leon, Andres</au><au>Gómez-Almaguer, David</au><au>Ruiz-Argüelles, Guillermo</au><au>Hernández-Hernández, Jose</au><au>Malpica, Luis</au><au>Sotomayor, Eduardo M.</au><au>Castillo, Jorge J.</au><aucorp>The Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</aucorp><aucorp>Latin American Group of Lymphoproliferative Disorders (Grupo de Estudio Latinoamericano de Linfoproliferativos [GELL])</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2020-10</date><risdate>2020</risdate><volume>20</volume><issue>10</issue><spage>637</spage><epage>646</epage><pages>637-646</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy.
The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis.
In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P = .006) and the validation cohort (odds ratio, 0.49; P = .01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P = .04) and the validation cohort (hazard ratio, 1.80; P = .003).
The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR ≥ 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.
We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma treated with chemoimmunotherapy. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis. In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response and worse survival in the learning and the validation cohort. The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32513598</pmid><doi>10.1016/j.clml.2020.04.016</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5330-9309</orcidid><orcidid>https://orcid.org/0000-0002-7082-1846</orcidid><orcidid>https://orcid.org/0000-0002-5478-714X</orcidid><orcidid>https://orcid.org/0000-0001-6188-8494</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2020-10, Vol.20 (10), p.637-646 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2411110487 |
| source | Elsevier ScienceDirect Journals |
| subjects | Biomarkers DLBCL NLR Overall survival Prognostic factor |
| title | A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A36%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Multi-Institutional%20Validation%20of%20the%20Prognostic%20Value%20of%20the%20Neutrophil-to-Lymphocyte%20Ratio%20in%20Patients%20With%20Diffuse%20Large%20B-Cell%20Lymphoma:%20A%20Study%20From%20The%20Latin%20American%20Group%20of%20Lymphoproliferative%20Disorders%20(GELL)&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Beltr%C3%A1n,%20Brady%20E.&rft.aucorp=The%20Latin%20American%20Group%20of%20Lymphoproliferative%20Disorders%20(Grupo%20de%20Estudio%20Latinoamericano%20de%20Linfoproliferativos%20%5BGELL%5D)&rft.date=2020-10&rft.volume=20&rft.issue=10&rft.spage=637&rft.epage=646&rft.pages=637-646&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2020.04.016&rft_dat=%3Cproquest_cross%3E2411110487%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2411110487&rft_id=info:pmid/32513598&rft_els_id=S2152265020302111&rfr_iscdi=true |